Fractyl Health's Positive Clinical Trial Data Boosts Stock

Fractyl Health shares are trading higher after announcing groundbreaking results from its REMAIN-1 Midpoint Cohort study, which showed Revita maintained weight loss post-GLP-1 drug discontinuation.